Business Context and Reporting Period
HeartBeam, Inc. filed this Form 8-K under Item 5.02 regarding a board appointment effective July 24, 2023. The company develops technology for cardiac monitoring; this filing does not provide operating or financial results.
Board Appointment
- Michael R. Jaff, age 64, was appointed to the Board of Directors effective July 24, 2023.
- The Board increased its size from seven to eight directors to accommodate the appointment.
- Dr. Jaff was not serving on a Board committee as of the filing.
- He is Chief Medical Officer and Vice President of Clinical Affairs, Technology and Innovation of Boston Scientific Corporation and has extensive experience in vascular medicine, clinical care, research, and medical-device innovation.
- The company stated that Dr. Jaff has no family relationship with current officers or directors and no reportable related-party transactions.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, capitalization, or other financial metrics.
Material Changes, Outlook, and Risks
- The material disclosed change is the addition of Dr. Jaff to the Board and the resulting increase in Board size.
- No financial guidance, business outlook, management forecast, contingencies, or unusual financial items are disclosed.
- A press release announcing the appointment was issued on July 26, 2023 and filed as Exhibit 99.1, although the appointment was effective July 24, 2023.
Investor Verification Items
- Review the related press release for additional details regarding Dr. Jaff’s appointment and expected contribution.
- Verify Dr. Jaff’s current employment and any potential governance or conflict considerations arising from his position at Boston Scientific.
- Consult the company’s periodic reports for financial performance, liquidity, funding requirements, and operating risks, which are not addressed in this filing.